GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sutro Biopharma STRO · USD

Health Care · US listing · 🇺🇸 United States

Compare

10.61

+10.29%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Sutro Biopharma annual report

Filed with the US Securities and Exchange Commission

10-K

The latest annual report covers the year to 31 Dec 2025, filed on 23 Mar 2026.

Read the 10-K on SEC.gov ↗

Five-year highlights

In USD.

FY2025FY2024FY2023FY2022FY2021
Revenue$102.5m$62.0m$153.7m$67.8m$61.9m
Operating income−$153.0m−$238.5m−$89.3m−$128.9m−$98.5m
Net income−$191.1m−$227.5m−$106.8m−$119.2m−$105.5m
Free cash flow−$178.9m−$194.6m−$115.9m−$4.3m−$97.0m
Total assets$173.8m$387.2m$470.7m$406.9m$341.4m
Shareholders' equity−$132.5m$44.6m$149.6m$217.0m$252.6m

Revenue by business

Year to 31 Dec 2025

  • Ongoing Performance Related to Unsatisfied Performance Obligations $31.9m · 31.1%
  • Financing Component on Unearned Revenue $3.4m · 3.3%
  • Research and Development Services $581,000 · 0.6%
  • Materials Supply $19,000 · 0.0%

Filings

Newest first, from SEC EDGAR

Sources and methodology

Data on this tab
SEC EDGAR and our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.